(Q39036930)

English

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

scientific article published on 18 February 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Mariano Provencio

object named as

Mariano Provencio

6

0 references

13

object named as

Rodryg Ramlau

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

György Losonczy

8

object named as

György Losonczy

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Aleksandra Szczesna

10

object named as

Aleksandra Szczesna

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Luis Paz-Ares

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Jörg Mezger

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Tudor E Ciuleanu

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Jürgen R Fischer

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Joachim von Pawel

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Andrzej Kazarnowicz

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Gilberto de Castro

9

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Lucio Crino

11

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Martin Reck

12

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Ernst Ulsperger

14

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Christian Schumann

15

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Jose Elias A Miziara

16

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Álvaro E Lessa

17

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Mircea Dediu

18

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Beatrix Bálint

19

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Henrik Depenbrock

20

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Victoria Soldatenkova

21

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Raffael Kurek

22

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Fred R Hirsch

23

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Nick Thatcher

24

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Mark A Socinski

25

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

INSPIRE investigators

26

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

publication date

18 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

328-337

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

New pathologic classification of lung cancer: relevance for clinical practice and clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Management and future directions in non-small cell lung cancer with known activating mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970046-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70046-X

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39036930&oldid=1803569883"